MARKET

ASRT

ASRT

Assertio Holdings Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.090
+0.110
+3.69%
Closed 17:59 05/26 EDT
OPEN
3.000
PREV CLOSE
2.980
HIGH
3.160
LOW
2.940
VOLUME
690.98K
TURNOVER
--
52 WEEK HIGH
3.519
52 WEEK LOW
0.8512
MARKET CAP
140.39M
P/E (TTM)
-227.2059
1D
5D
1M
3M
1Y
5Y
--BWS Financial Initiates Assertio Therapeutics at Buy, $6 Price Target
MT Newswires · 05/18 12:17
36 of the Best Ideas Companies to Present at the Spring into Action - Best Ideas Investor Conference on May 16th - 20th, 2022
RALEIGH, NC / ACCESSWIRE / May 16, 2022 / The Spring into Action- Best Ideas Virtual Investor Conference will take place on May 16th \- 20th, 2022, where 36 SmallCap, MicroCap and NanoCap public companies will be presenting via virtual webcast to a global ...
ACCESSWIRE · 05/16 17:20
Is Assertio (ASRT) Stock Outpacing Its Medical Peers This Year?
Here is how Assertio (ASRT) and Sensus Healthcare, Inc. (SRTS) have performed compared to their sector so far this year.
Zacks · 05/13 13:40
52 Stocks Moving In Wednesday's Mid-Day Session
Gainers Trecora Resources (NYSE: TREC) shares jumped 26.6% to $9.56 as the company agreed to be acquired by an affiliate of Balmoral Funds at $9.81 per share in cash or an enterprise value of $247 million.
Benzinga · 05/11 16:25
Assertio Posts Higher Q1 Sales, Profits; Lifts FY22 Adjusted EBITDA Outlook
Benzinga · 05/10 18:44
77 Stocks Moving In Tuesday's Mid-Day Session
Gainers
Benzinga · 05/10 16:01
Biohaven, AdaptHealth top healthcare gainers; Bausch Health, GoodRx lead losers' pack
Gainers: Biohaven Pharmaceutical (BHVN) +71%. AdaptHealth (AHCO) +31%. Evaxion Biotech (EVAX) +25%. Assertio (ASRT) +22%. Haemonetics (HAE) +16%. Losers: Bausch Health (BHC) -26%. GoodRx (GDRX) -24%. Akanda (AKAN) -21%. Novavax (NVAX) -12%. Blue Water Vacc...
Seekingalpha · 05/10 14:02
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Investor Place · 05/10 11:25
More
No Data
Learn about the latest financial forecast of ASRT. Analyze the recent business situations of Assertio Holdings Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
100.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average ASRT stock price target is 5.75 with a high estimate of 6.00 and a low estimate of 5.50.
High6.00
Average5.75
Low5.50
Current 3.110
EPS
Actual
Estimate
-0.21-0.090.020.14
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 187
Institutional Holdings: 12.43M
% Owned: 27.36%
Shares Outstanding: 45.43M
TypeInstitutionsShares
Increased
16
1.33M
New
17
1.27M
Decreased
8
231.27K
Sold Out
7
168.33K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.69%
Pharmaceuticals & Medical Research
+1.28%
Key Executives
Non-Executive Chairman/Independent Director
Peter Staple
President/Chief Executive Officer/Director
Daniel Peisert
Chief Financial Officer/Senior Vice President
Paul Schwichtenberg
Senior Vice President/Chief Accounting Officer
Ajay Patel
Senior Vice President/General Counsel
Sam Schlessinger
Independent Director
Heather Mason
Independent Director
William Mckee
Independent Director
James Tyree
No Data
No Data
About ASRT
Assertio Holdings, Inc. is a commercial pharmaceutical company offering differentiated products to patients. The Company's commercial portfolio of branded products focuses on three areas: neurology, hospital, and pain and inflammation. Its marketed products include Cambia (diclofenac potassium) for Oral solution, INDOCIN Oral Suspension, INDOCIN (indomethacin) Suppositories, OXAYDO (oxycodone HCI, USP) tablets, SPRIX (ketorolac tromethamine) Nasal Spray, and ZIPSOR (diclofenac potassium) Liquid filled capsules. INDOCIN products are used for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease, moderate to severe ankylosing spondylitis, moderate to severe osteoarthritis, acute painful shoulder (bursitis and/or tendinitis) and acute gouty arthritis. CAMBIA (diclofenac potassium) is used for the acute treatment of migraine attacks with or without aura in adults 18 years of age or older.

Webull offers kinds of Assertio Holdings Inc stock information, including NASDAQ:ASRT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ASRT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ASRT stock methods without spending real money on the virtual paper trading platform.